Response Genetics, Inc. to Offer ROS1 Testing for Lung Cancer

Published November 10, 2012

Response Genetics, Inc. to Offer ROS1 Testing for Lung Cancer
Filed under: dual diagnosis drug treatment

5, 2012 — /PRNewswire/ — Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today the launch of testing for ROS1 gene rearrangements. Recently, the Massachusetts …
{Source}

YM Biosciences Offers Interim Results from Jak Inhibitor CYT387 Study; Sanofi …
Filed under: dual diagnosis drug treatment

{nfg}YM BioSciences Inc. (NYSE: YMI) reported interim results from the Phase I/II study of CYT387, a JAK1/JAK2 inhibitor currently being evaluated for the treatment of myelofibrosis, which were included in an abstract submitted to the American Society …
{Source}